Introduction: Glucocorticoid-remediable aldosteronism (GRA) is a rare inherited cause for hypertension associated with a significant morbidity and mortality at an early age. Individuals with this abnormality frequently present with severe hypertension which is resistant to standard antihypertensive therapy, a strong family history of hypertension, intracranial haemorrhage, and sporadic hypokalaemia. However many affected individuals may appear phenotypically indistinguishable from normal essential hypertensives but remain at high risk of morbidity and mortality. Objective: To determine how effective random or targeted screening of hypertensive patients is for the detection of GRA. Design: A prospective study involving the screening of 300 hypertensive patients chosen at random attending the Aberdeen Hypertension Clinic and, during the same
Introduction
The relatively high prevalence of hypertension (approximately 15%) in our society exerts a significant impact on the risk for stroke, cardiovascular and renal disease. In the majority of hypertensive patients, no single specific etiological factor can be identified and the hypertension seems to be multifactorial in origin. However, there is evidence that the risk of hypertension clusters in families, 1 therefore family history of hypertension can provide a strong indicator of risk. 2 Glucocorticoid-remediable aldosteronism (GRA) is a rare autosomal dominant 3 cause of primary aldosteronism originally described in a father and son by Sutherland et al. 4 Both were found to have hypertension associated with low plasma potassium concentration, increased aldosterone secretion, increased plasma volume and suppressed plasma renin activity; all of which were reversed by dexamethasone therapy. Further cases of severe hypertension usually presenting at a young age with signs of primary aldosteronism, in association with family history of hypertension [5] [6] [7] [8] and cerebral haemorrhage have been described. 7, 8 The molecular basis for GRA was reported by Lifton and co-workers in 1992. 9 Patients with GRA have an abnormal chimaeric gene which results from the unequal crossing-over of two genes, aldosterone synthase and 11␤-hydroxylase, which both lie on chromosome 8q and are Ͼ95% homologous 10 ( Figure 1 ). In this rearranged gene the coding sequences for 11␤-hydroxylase are fused to the coding sequences for aldosterone synthase resulting in the abnormal synthesis of aldosterone in response to adrenocorticotrophic hormone (ACTH) and leading to the development of primary hyperaldosteronism and hypertension. Glucocorticoids inhibit ACTH secretion and therefore suppress aldosterone production and normalise both blood pressure (BP) and the metabolic abnormalities of primary aldosteronism. The presence of the chimaeric gene can be identified by DNA analysis and Southern blotting as previously described by Lifton et al. 9 We originally identified two index cases attending the Aberdeen Hypertension Clinic and from these two a total of 30 patients who possess the abnormal 6.3 kilobase genomic DNA fragment which is tightly linked to GRA have been identified. The majority of affected family members have mild-to-moderate hypertension and normal biochemistry and are clinically indistinguishable from patients with essential hypertension. It is therefore possible that this condition is under-diagnosed. This form of hypertension is noteworthy because it is frequently unresponsive to standard antihypertensive medication but successfully managed by treatment with amiloride, spironolactone or dexamethasone 4, [11] [12] [13] alone. Worryingly GRA is associated with a high associated morbidity and mortality at a young age in those affected individuals with severe hypertension. Whether the presence of severe hypertension also plays a part in the high incidence of acute cerebral haemorrhage in young affected individuals is unknown. However the expected benefit from the early identification, treatment and regular BP monitoring of GRA-positive individuals these cases is likely to be high.
Methods
Three hundred patients attending the Aberdeen Hypertension Clinic were randomly selected and screened for GRA. At the same time targeted screening was offered to individuals with a clinical picture and/or family history suggestive of GRA. Ten ml of blood were taken, DNA extracted using standard techniques and the samples screened for GRA using Southern blotting. 9 In normal subjects, when genomic DNA is digested with the restriction enzyme BamH1, Southern blotted and probed with a 11␤-hydroxylase specific probe there are two bands on the resultant autoradiograph of 8.5 and 4.5 kilobases, corresponding to 11␤-hydroxylase and aldosterone synthase respectively. When genomic DNA from affected subjects is examined, the presence of a chimaeric gene results in a restriction fragment length polymorphism ( Figure 2 ) and a third band on the autoradiograph.
Results
Random selection of patients did not identify a single individual with the GRA mutation, however targeted screening identified two index cases and a further four individuals together with 10 members of their families who proved to be GRA positive.
Index cases
The two index cases, who we have previously described 14 were initially identified because of their typical histories suggestive of GRA. The first had been identified at the age of 15 years as significantly hypertensive and at the time of testing had a 31-year history of resistant hypertension, hypokalaemia and a strong maternal family history of hypertension with a history of cerebral haemorrhage in the maternal grandmother. Fourteen further members of this family have since been identified as possessing the chimaeric gene strongly linked to GRA, 12 were hypertensive (10 known, two previously undiagnosed), and two at the time of screening were normotensive and normokalaemic.
The proband of the second index family had a similar history with a 10-year history of severe hypertension diagnosed at the age of 15 years, a strong maternal family history of hypertension and of cerebral haemorrhage, and diuretic-induced hypokalaemia.
A further 14 members of his family have proven positive for the abnormal chimaeric gene. Again, there is a spectrum of severity of clinical features; four were normotensive and normokalaemic, while five were hypertensive from their late teens. The remaining five GRA-positive individuals proved to have mild hypertension but no hypokalaemia at the time of investigation. The wide variation in phenotype of those possessing the GRA mutation is clearly illustrated by the immediate family members of both of these index cases.
Targeted screening
Targeted screening of hypertensive individuals with a history of resistant hypertension, a family history of intracranial haemorrhage or resistant hypertension and or a history of hypokalaemia identified a further four GRA-positive individuals together with 10 GRA-positive family members.
The proband for the third family, a 30-year-old man, was found to be hypertensive during a medical examination (BP: 170/120 mm Hg). Because of the presence of hypokalaemia, a strong maternal family history of hypertension (mother, three of mother's four siblings) and also the history of the death of an uncle from cerebral haemorrhage at a young age, he was screened and found positive for the GRA gene as were three members of his direct family.
The proband of the fourth family who had been treated for hypertension for 29 years with betablocker and thiazide diuretic, also demonstrated a typical history. Although she had a normal serum biochemistry, she was screened for GRA because of a strong family history of hypertension and, in particular, a history of known primary aldosteronism in Journal of Human Hypertension her mother and of two maternal uncles both of whom died from cerebral haemorrhage.
The proband of the fifth family had a 19-year history of hypertension since age 28. At the time of diagnosis he was receiving triple antihypertensive therapy (atenolol, enalapril and bendrofluazide). He was screened because of the presence of a persistent mild hypokalaemic alkalosis and family history of hypertension but no known incidence of intracranial bleed.
The proband of the sixth family was a 36-year-old male who presented, following an insurance medical, with significant hypertension uncontrolled by amlodipine 5 mg (165/100 mm Hg, 24-h ambulatory BP monitoring (ABPM) average BP), left ventricular hypertrophy (LVH) on ECG, a strong family history of hypertension and a strong family history of intracranial haemorrhage affecting three members of the family (maternal aunt and two nieces). Previous medicals had reported entirely normal BPs as had an insurance medical 2 years earlier (132/86 mm Hg), suggesting that he had developed severe hypertension at a later age. He was screened for GRA and proved positive as did his mother (166/88 mm Hg, 24-h ABPM average BP, on dual therapy) and one brother (113/73 mm Hg, 24-h ABPM average BP) and sister (107/62 mm Hg, 24-h ABPM average BP) and one of her children (3 years of age). Only he and his mother were hypertensive, both his brother and sister were normotensive and normokalaemic. Sixteen further members of his family were tested for GRA and one maternal aunt and two of her sons were also found to be GRA-positive, all three were receiving medication for hypertension. None of these family members had a history of hypokalaemia. The proband and his mother responded well to the addition of amiloride and 24-h ABPM average BPs settled to 120/83 mm Hg and 129/77 mm Hg respectively.
Discussion
It is evident that GRA-positive individuals present with a spectrum of clinical features. The majority of mutation-positive family members are clinically indistinguishable from patients with essential hypertension. In view of this it was felt that GRA is possibly under-diagnosed and may not be as rare as originally thought. For these reasons we undertook to screen 300 randomly selected attendants of the Aberdeen Hypertension Clinic. However random screening of patients attending the hypertension clinic failed to reveal a single mutation-positive individual.
Individuals affected with GRA may present with a spectrum of disease. We have currently identified 40 mutation positive individuals (including five currently under the age of 16 years) in six families. Of these 30 currently require treatment for hypertension with eight having developed severe hypertension in their teenage years. Few have evident hypokalaemic alkalosis, usually hypokalaemia became apparent when potassium homeostasis was stressed following treatment with low-dose thiazide diuretic. The majority of GRA-positive individuals were in all respects clinically and biochemically indistinguishable from patients with essential hypertension.
The diagnosis of this form of secondary hypertension is of considerable importance because the associated morbidity and mortality is high and standard antihypertensive medication may be of little use in those with severe hypertension. A further concern is the high incidence of intracerebral haemorrhage (11-18%) with a high associated mortality (61%) at an early age (31.7 ± 11.3 years) among GRA-positive individuals. 15 In previous reports the youngest subject to suffer from an intracranial haemorrhage was 30 years of age, in this study the youngest individual to die from an intracranial haemorrhage was 17 years old. Although there is little detail about the effectiveness of antihypertensive treatment in preventing such catastrophic outcomes it must be assumed that the aggressive treatment of even borderline hypertension with amiloride, spironolactone or low-dose dexamethasone alone or in combination with other antihypertensive therapy should be expected to result in benefit.
Clearly identification of at risk individuals, even at an early age (in this cohort three individuals under the age of 5 years were screened and one found positive), is important because initiation of appropriate monitoring in affected but normotensive individuals, and simple and effective treatment of hypertensive individuals early in life may prevent the complications associated with severe hypertension, premature death and disability from stroke. The expected benefit from identification and treatment of these cases is therefore high and clearly the implications for the individuals concerned and their families for the prevention of premature death and disability are major.
While targeted screening appears effective, random screening of hypertensive individuals is of no value in the diagnosis of GRA. Hypertensive individuals with a strong family history of hypertension, especially with a family history of cerebral haemorrhage, a history of hypertension from an early age, hypokalaemic alkalosis, and hypertension which has proven difficult to control despite multiple drug therapy, should be screened for GRA because of the expected benefit to the individuals in terms of BP control and prevention of resultant complications from the appropriate simple and effective treatment.
Conclusions
GRA is a rare inherited cause for severe hypertension which is frequently identical to essential hypertension but which is associated with a high morbidity and mortality at an early age. There are however indicators to the presence of GRA, which include a family history of hypertension and of cerebral haemorrhage, a history of hypertension from an early age, hypertension which has proven difficult to control and hypokalaemia. In such individuals these signs should not be ignored because good BP control can often be achieved with simple treatment such as amiloride, spironolactone or dexamethasone.
